A novel 5-way translocation t(9;11;13;19;22) in a case of chronic-phase chronic myeloid leukemia

Hum Pathol. 2013 Oct;44(10):2365-9. doi: 10.1016/j.humpath.2013.02.021. Epub 2013 Jun 4.

Abstract

Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder that occurs because of t(9;22)(q34;q11) translocations. Complex translocations have been reported in CML. We report a novel 5-way translocation 46,XY,t(9;11;13;19;22)(9q34.12;11p11.12;13q21.31;19q13.12;22q11.21) using GTG banding, fluorescence in situ hybridization, and spectral karyotyping in a case of chronic-phase CML. Molecular analysis revealed the presence of 2 types of transcripts (b3a2, b2a2). The patient was responding to the imatinib treatment. However, the patient needs to be carefully monitored at various intervals.

Keywords: 5-Way translocation; BCR/ABL gene; Chronic myeloid leukemia; Chronic phase.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Benzamides / therapeutic use
  • Chromosomes, Human, Pair 11* / genetics
  • Chromosomes, Human, Pair 13* / genetics
  • Chromosomes, Human, Pair 19* / genetics
  • Chromosomes, Human, Pair 22* / genetics
  • Chromosomes, Human, Pair 9* / genetics
  • Humans
  • Imatinib Mesylate
  • In Situ Hybridization, Fluorescence
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Male
  • Piperazines / therapeutic use
  • Pyrimidines / therapeutic use
  • Spectral Karyotyping
  • Translocation, Genetic / genetics*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate